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Abstract
The aim of this study was to determine the characteristics and shifts in serotype distribution of pneumococcal isolates causing ocular
infections in a region of northern Spain in two periods: 1999–2010 for episodes of conjunctivitis (n = 612) and 1980–2010 for uncommon
and more severe non-conjunctival ocular infections (n = 36). All isolates were serotyped and non-typeable isolates were confirmed as
unencapsulated by multiplex-PCR of the lytA, ply and cpsA genes. Genotyping was done by pulsed-field gel electrophoresis and multi-locus
sequence typing. Most conjunctivitis cases occurred in children under 5 years old (89.5%), and more severe non-conjunctival ocular
infections occurred in patients older than 25 years (86.1%). Unencapsulated isolates were detected in 213 conjunctivitis episodes (34.8%)
and one non-conjunctival infection (2.8%). Rates of unencapsulated isolates were similar throughout the study. Among 399 conjunctival
encapsulated isolates, the most prevalent were serotypes 19A (n = 53), 15B (n = 30), 6A (n = 27), 19F (n = 25), 23F (n = 21) and 6B
(n = 17). The most prevalent serotypes in non-conjunctival infections were serotype 3 (n = 4), 23F (n = 4), 6B (n = 3) and 19A (n = 3).
Conjunctivitis caused by serotypes included in the hepta-valent pneumococcal conjugate vaccine steadily decreased, accounting for 34.9%
(22/63) in 1999–2001, 19.7% (23/117) in 2002–04, 13.6% (33/242) in 2005–07 and 3.2% (6/190) in 2008–10. Among the 213 unencapsulated
isolates, 31 different pulsed-field gel electrophoresis patterns were identified. The main clonal complexes (CC) were CC941 (ST941,
ST942), CC448 (ST448) and CC344 (ST344, ST3097). CC941 was the predominant CC in 1999–2001, 2002–04 and 2005–07, being
replaced by CC448 in 2008–10. The multidrug-resistant CC344 was present throughout the study.
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Introduction
Conjunctivitis is the ophthalmic infection most frequently seen
by general practitioners, causing high healthcare expenditure.
One of the major aetiological agents is Streptococcus pneumo-
niae [1]. Pneumococcal conjunctivitis usually has a benign
course and rarely gives rise to complications. As topical
antimicrobial treatment ensures the clinical resolution of
superficial pneumococcal eye infections, study of the epidemi-
ology of conjunctivitis has been scarce, consisting mostly of
descriptions of large outbreaks [2,3]. Pneumococci, on the
other hand, can also cause endophthalmitis and other more
severe ophthalmic infections [4,5].
The pneumococcal polysaccharide capsule is a virulent
factor that protects pneumococci from opsonophagocytosis
and is the target of current pneumococcal vaccines
developed to prevent invasive pneumococcal disease [6].
The hepta-valent pneumococcal conjugate vaccine (PCV7)
for childhood vaccination was introduced in Spain in late
2001.
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Conjugate vaccines have been demonstrated to exert herd
protection, preventing invasive and non-invasive pneumococcal
infections both in the vaccinated and unvaccinated populations
[7,8]. Due to a reduction in the nasopharyngeal carriage of
vaccine serotypes, this herd protection effect could also
provoke a change in the distribution of pneumococci causing
conjunctivitis. The association of non-typeable pneumococci
with conjunctivitis was already suggested by Finland and Barnes
in 1977 [9]. Indeed, unencapsulated pneumococci have caused
several conjunctivitis outbreaks in the USA [2,10,11] and are
also recognized as a frequent cause of sporadic cases of
conjunctivitis in Spain [12]. So far, little is known about the
influence of PCV7 on the prevalence of serotypes causing
conjunctivitis.
The main aim of this study was to analyse the distribution of
pneumococcal serotypes causing conjunctivitis over a 12-year
period, to analyse the influence of the introduction of PCV7 on
pneumococcal conjunctivitis, and to characterize unencapsu-
lated isolates molecularly. Episodes from non-conjunctival
infections were included mainly to compare types of isolates
and patients’ age and other characteristics.
Materials and Methods
Study design, patients and isolates
The study was conducted at Hospital Universitario Donostia,
an 1100-bed hospital located in the city of San Sebastian
province of Gipuzkoa, Basque Country, northern Spain. The
hospital serves an estimated general population including
children of 350 000 inhabitants from the region of Donostial-
dea and adjacent areas and is the referral hospital for the
province.
All S. pneumoniae isolates recovered from 1999 to 2010 in
the conjunctival exudates of patients diagnosed with conjunc-
tivitis by their paediatrician, general practitioner or, less
frequently, their ophthalmologist of the areas served by the
hospital were included in the study. From 1980 to 2010, other
pneumococcal isolates obtained from more severe ophthalmic
infections were also characterized. The longer study period in
the non-conjunctival ocular infections was because of the low
incidence of these types of pneumococcal infections. Demo-
graphic and clinical data were obtained by reviewing the
patients’ medical records. In this study, the patients received
no direct interventions other than the regular healthcare
activity of our centre. Publication of the results was approved
by the Ethics Committee for Clinical Research of the Health
Area of Gipuzkoa.
If the same serotype was isolated in two conjunctival
samples from the same patient, the serotypes were considered
as being from different episodes if the specimens had been
collected at least 3 months apart. If a different serotype was
isolated from the same patient, each isolate was considered as
a different episode regardless of the time between the two
episodes.
The evolution of serotypes causing conjunctivitis was
analysed in four study periods of 3 years each: one pre-
PCV7 vaccination period, from 1999 to 2001, and three post-
PCV7 vaccination periods: an early period from 2002 to 2004,
an intermediate period from 2005 to 2007, and a late post-
PCV7 period from 2008 to 2010. During the study period, the
PCV7 was not included in the official vaccination schedule of
the public health system of the Basque Country, being only
dispensed in private practice. There are no official data of
PCV7 coverage, but based on the number of doses sold in
Gipuzkoa, the estimated vaccine coverage rate in children
under 2 years of age was close to 50% before 2006 and 60% in
2009.
Microbiological and molecular procedures
Conjunctival exudates were collected with a swab and sent for
microbiological analysis in Stuart or a similar transport
medium. Other ocular samples from more severe ophthalmic
infections were obtained by swabbing, scraping or needle
puncture. Samples were cultured on blood agar and chocolate
agar plates and were incubated for 18–24 h at 35°C in a 5%
CO2-enriched atmosphere. The S. pneumoniae isolates were
identified on the basis of their typical colony morphology,
a-haemolysis on blood agar, optochin sensitivity and bile
solubility. Serotyping was performed with the Quellung
reaction using polyclonal antisera (Statem Serum Institut,
Copenhagen, Denmark), or an antibody-based microarray
serotyping technique (Pneumoarray, Abyntek, Spain) or by
multiplex PCR [13].
To confirm that non-typeable S. pneumoniae isolates were
indeed unencapsulated pneumococci, a multiplex PCR con-
taining primers for the amplification of the capsular cpsA gene,
a gene common to all types of capsular locus [14], and of the
pneumococcal specific autolysin (lytA) and pneumolysin (ply)
genes, was performed [15–17]. Isolates giving a negative
serotype reaction by the three typing techniques and ampli-
fying the lytA and ply genes but not the cpsA capsular gene were
considered as unencapsulated pneumococci.
Pulsed-field gel electrophoresis (PFGE) was performed as
previously described [18] in all unencapsulated and all serotype
19A isolates, the two groups of isolates most frequently
causing conjunctivitis in our study. Isolates with a PFGE pattern
similarity of >85% were considered to belong to the same
pattern. In this study, PFGE patterns were arbitrarily named A
to Z.
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Within each pattern and depending on their differences, the
sequence types (ST) of representative isolates were deter-
mined (one to five isolates for each cluster of isolates with
100% similarity, up to 12 total isolates per pattern). The ST
was determined using the primers and conditions described in
the pneumococcal multilocus sequence-type (MLST) web site
(http://www.mlst.net).
If different STs were detected within the same PFGE pattern
by MLST of the seven alleles, then the remaining isolates with
the same PFGE and susceptibility patterns were presumptively
associated with each ST by sequencing one of the alleles that
differentiated between both STs (e.g. ddl in isolates with PFGE
patterns A and B, gdh among pattern C isolates).
Antimicrobial susceptibility testing was performed by the
broth microdilution method using the CLSI guidelines and
criteria [19]. All isolates were tested for susceptibility to
penicillin, amoxicillin, erythromycin, clindamycin, tetracycline,
trimethoprim-sulfamethoxazole, ciprofloxacin, chlorampheni-
col and rifampicin.
Statistical analysis
Discrete variables were analysed by the chi-square test or the
Fisher exact test and analysis of trends over time was
calculated using the chi-square test for trend with the
GRAPHPAD INSTAT version 3.05 software (GraphPad Software
Inc., La Jolla, CA, USA).
Results
Patients and isolates
From 1999 to 2010, 612 pneumococcal isolates were obtained
from conjunctival exudates from 587 patients and all of them
were included in the study. Of these conjunctivitis episodes,
588 (96.1%) were diagnosed in children aged <15 years, and
548 (89.5%) were from children <5 years old.
In 210 (34.3%) conjunctivitis episodes, the pneumococcus
was isolated with other potential pathogenic bacteria: Haemo-
philus influenzae (n = 169), Staphylococcus aureus (n = 18),
gram-negative bacilli (n = 10), Moraxella catarrhalis (n = 10),
Streptococcus pyogenes (n = 2) and in one episode with another
two potential pathogens (Staphylococcus aureus and H. influen-
zae).
All isolates from severe non-conjunctival ocular infections
detected from 1980 to 2010 were included in this study: 18
from endophthalmitis (50%), one from panophthalmitis (2.8%),
ten from corneal abscesses (27.8%), six from dacryocystitis
(16.7%), and one from a scleral abscess (2.8%).
Unlike conjunctivitis, 86.1% of these 36 severe pneumo-
coccal ocular infections occurred in patients aged >25 years,
and 50% (n = 18) occurred in patients aged >69 years. In
11.1% (4/36) of severe ocular infections, pneumococcus was
isolated as a mixed infection.
Of six patients with dacryocystitis, pneumococcus was
isolated as a mixed infection with H. influenzae in two patients
and with Staphylococcus aureus in one patient. Pneumococcus
was isolated as a mixed infection with Candida parapsilosis in
one patient with endophthalmitis.
Serotype distribution
Of 612 conjunctivitis episodes, 213 (34.8%) were caused by
unencapsulated isolates (Table 1). The percentage of unen-
capsulated isolates was similar in the four study periods: 20/63
(31.7%, 95% CI: 20.2–43.2) in 1999–2001, 39/117 (33.3%, 95%
CI: 24.8–41.8) in 2002–04, 90/242 (37.2%, 95% CI: 31.1–43.3)
in 2005–07, and 64/190 (33.7%; 95% CI: 27.0–40.4) in 2008–10
(chi-square for trend, p 0.9).
Among the 399 encapsulated isolates causing conjunctivitis,
the most prevalent serotypes during the 12-year study were
serotypes 19A (n = 53, 8.7% of total 612 conjunctival pneu-
mococci), 15B (n = 30, 4.9%), 6A (n = 27, 4.4%), 19F (n = 25,
4.1%), 23F (n = 21, 3.4%) and 6B (n = 17, 2.8%).
Conjunctivitis caused by PCV7 serotypes decreased over
time: 34.9% (22/63) in 1999–2001, 19.7% (23/117) in 2002–04,
13.6% (33/242) in 2005–07 and 3.2% (6/190) in 2008–10 (p for
trend p <0.001). This significant decreasing trend was also
observed when PCV7 serotypes 19F, 23F and 6B were
individually considered (p for trend for each serotype
p <0.01).
The percentage of conjunctivitis episodes caused by sero-
type 19A increased from 4.8% (3/63) in 1999–2001 to 11.1%
(21/190) in 2008–10, whereas those caused by serotype 6A
decreased in the same periods from 7.9% (5/63) to 3.2% (6/
190) but none of these changes reached statistical significance.
The distribution of serotypes causing non-conjunctival
severe ocular infections showed greater heterogeneity
(Table 2).
Only one (2.8%) non-conjunctival episode was produced by
an unencapsulated isolate. The patient was a 3-month-old girl
with acute dacryocystitis progressing toward chronicity.
Molecular characterization
The 213 unencapsulated pneumococci causing conjunctivitis
were studied by PFGE. Overall, 31 different PFGE patterns
were found, among which four main patterns that grouped 176
(82.6%) of the 213 isolates studied were identified and
arbitrarily named A to D (Table 3).
PFGE patterns A and B showed 75% similarity but ST941
and ST942 isolates were detected in both patterns. These two
STs belonged to the clonal complex (CC) 941.
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Two STs (344 and 3097) were detected among pattern C
isolates. ST3097 is a single-locus variant of ST344 and both
belonged to CC344.
Most isolates with pattern D (31/34) had 100% similarity
and only one ST (ST448) was detected, which is the
representative ST of CC448.
CC941 (ST941, ST942) isolates predominated between
1999 and 2006, exceeding ST448 by a ratio of 3 to 1 during
this period. Since 2007, CC941 almost disappeared, being
displaced by ST448, which was the main clone among
unencapsulated pneumococci causing ocular infections in the
last 4 years of the study. CC344 (ST344 and ST3097) isolates
were present in all four study periods, ST3097 being more
prevalent than ST344.
All 53 conjunctival serotype 19A isolates were studied by
PFGE and showed 21 different PFGE patterns. Pattern E
grouped ten ST193 isolates that showed penicillin susceptibility
but erythromycin, clindamycin and tetracycline resistance.
Pattern F grouped nine ST276 isolates that were non-
susceptible to penicillin, erythromycin, clindamycin, tetracy-
cline and trimethoprim-sulfamethoxazole. Another PFGE
pattern (pattern G, ST320), with four isolates detected from
2008 to 2010, was non-susceptible to penicillin, amoxicillin,
erythromycin, clindamycin, tetracycline and trimethoprim-
TABLE 1. Serotype distribution and prevalence of unencapsulated isolates among pneumococci causing conjunctivitis in
Donostialdea and adjacent populations (Gipuzkoa, Basque Country, northern Spain) from 1999 to 2010
Serotypes
Pre-vaccination
1999–2001
(n = 63)
Early post-PCV7
2002–04
(n = 117)
Intermediate
post-PCV7
2005–07
(n = 242)
Late post-PCV7
2008–10
(n = 190)
Total 1999–2010
(n = 612)
1 0 0% 1 0.9% 4 1.7% 2 1.1% 7 1.1%
3 1 1.6% 2 1.7% 3 1.2% 4 2.1% 10 1.6%
4 0 0% 0 0% 0 0% 0 0% 0 0%
5 0 0% 0 0% 0 0% 0 0% 0 0%
6A 5 7.9% 8 6.8% 8 3.3% 6 3.2% 27 4.4%
6B 2 3.2% 9 7.7% 6 2.5% 0 0% 17 2.8%
6C 0 0% 3 2.6% 7 2.9% 5 2.6% 15 2.5%
7A 0 0% 0 0% 0 0% 1 0.5% 1 0.2%
7B/C 0 0% 1 0.9% 0 0% 0 0% 1 0.2%
7F 1 1.6% 0 0% 4 1.7% 2 1.1% 7 1.1%
8 0 0% 2 1.7% 3 1.2% 1 0.5% 6 1%
9L 1 1.6% 0 0% 0 0% 0 0% 1 0.2%
9N 1 1.6% 1 0.9% 1 0.4% 2 1.1% 5 0.8%
9V 3 4.8% 0 0% 5 2.1% 1 0.5% 9 1.5%
10A 0 0% 3 2.6% 4 1.7% 4 2.1% 11 1.8%
11A 1 1.6% 2 1.7% 6 2.5% 0 0% 9 1.5%
11B/C 0 0% 1 0.9% 0 0% 0 0% 1 0.2%
11F/D 1 1.6% 2 1.7% 6 2.5% 6 3.2% 15 2.5%
14 3 4.8% 1 0.9% 5 2.1% 1 0.5% 10 1.6%
15A 1 1.6% 0 0% 2 0.8% 5 2.6% 8 1.3%
15B 1 1.6% 4 3.4% 8 3.3% 17 8.9% 30 4.9%
15C 0 0% 0 0% 0 0% 1 0.5% 1 0.2%
16A 0 0% 0 0% 1 0.4% 0 0% 1 0.2%
16F 0 0% 2 1.7% 2 0.8% 3 1.6% 7 1.1%
17F 0 0% 0 0% 2 0.8% 4 2.1% 6 1%
18C 0 0% 0 0% 2 0.8% 0 0% 2 0.3%
19A 3 4.8% 7 6% 22 9.1% 21 11.1% 53 8.7%
19F 10 15.9% 7 6% 5 2.1% 3 1.6% 25 4.1%
20 0 0% 0 0% 2 0.8% 1 0.5% 3 0.5%
21 0 0% 3 2.6% 7 2.9% 4 2.1% 14 2.3%
22F 1 1.6% 1 0.9% 2 1.2% 2 1.1% 7 1.1%
23A 1 1.6% 3 2.6% 4 1.7% 1 0.5% 9 1.5%
23B 0 0% 1 0.9% 3 1.2% 12 6.3% 16 2.6%
23F 4 6.3% 6 5.1% 10 4.1% 1 0.5% 21 3.4%
24B 0 0% 1 0.9% 2 0.8% 1 0.5% 4 0.7%
27 0 0% 0 0% 3 1.2% 0 0% 3 0.5%
29 0 0% 0 0% 1 0.4% 2 1.1% 3 0.5%
31 0 0% 0 0% 0 0% 5 2.6% 5 0.8%
32F 0 0% 0 0% 0 0% 1 0.5% 1 0.2%
33F 1 1.6% 0 0% 1 0.4% 3 1.6% 5 0.8%
34 0 0% 1 0.9% 1 0.4% 0 0% 2 0.3%
35A 0 0% 1 0.9% 0 0% 0 0% 1 0.2%
35B 1 1.6% 1 0.9% 2 0.8% 2 1.1% 6 1%
35F 1 1.6% 2 1.7% 3 1.2% 1 0.5% 7 1.1%
36 0 0% 2 1.7% 0 0% 0 0% 2 0.3%
37 0 0% 0 0% 2 0.8% 0 0% 2 0.3%
39 0 0% 0 0% 1 0.4% 1 0.5% 2 0.3%
40 0 0% 0 0% 1 0.4% 0 0% 1 0.2%
Unencapsulated 20 31.7% 39 33.3% 90 37.2% 64 33.7% 213 34.8%
Total PCV7 serotypesa 22 34.9% 23 19.7% 33 13.6% 6 3.2% 84 13.7%
Total PCV10 serotypesb 23 36.5% 24 20.5% 41 16.9% 10 5.3% 98 16%
Total PCV13 serotypesc 32 50.8% 41 35% 74 30.6% 41 21.6% 188 30.7%
aPCV7: number of isolates of serotypes included in the PCV7 (serotypes 4, 6B, 9V, 14, 18C, 19F and 23F).
bPCV10: number of isolates included in the PCV10 (PCV7 serotypes plus serotypes 1, 5, and 7F).
cPCV13: number of isolates included in the PCV13 (PCV10 serotypes plus serotypes 3, 6A and 19A).
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sulfamethoxazole. The remaining 18 PFGE patterns (30
isolates) of serotype 19A isolates grouped one or two isolates,
most of them penicillin and erythromycin susceptible, but were
not further characterized by MLST.
Antimicrobial susceptibility
Conjunctival unencapsulated isolates were more often resis-
tant to oral penicillin (49.3%) than isolates belonging to PCV7
serotypes (31%, p <0.001). Only 16.5% of isolates of non-
PCV7 serotypes showed resistance to oral penicillin (Table 4).
None of the unencapsulated isolates, but 11.5% of the PCV7
serotypes, showed a penicillin MIC  4 µg/mL.
Erythromycin non-susceptibility was present in 41.7%,
25.4% and 27.2% of PCV7 serotypes, non-PCV7 serotypes
and unencapsulated isolates, respectively. The rate of trimeth-
oprim-sulfamethoxazole non-susceptibility was very high in
unencapsulated isolates (60.6%). Non-susceptibility to chl-
oramphenicol and rifampicin was present in 1% and 2.5% of the
total conjunctival pneumococci, respectively, and in 0% and
1.4% of unencapsulated isolates, respectively.
In general, the percentage of isolates showing antimicrobial
resistance decreased over the study period (Table 5) mainly as
the result of a reduction of the prevalence of PCV7 serotypes
and the increase of antimicrobial-susceptible CC448 isolates.
By genotype, many unencapsulated isolates showing the
PFGE patterns A and B (CC941: ST941 and ST942) also
showed penicillin and trimethoprim-sulfamethoxazole non-
susceptibility. ST942 isolates showed slightly higher penicillin
MICs (MIC50 = 0.50 lg/mL, range 0.25–1 lg/mL) than ST941
isolates (MIC50 = 0.12 lg/mL, range <0.03–0.25 lg/mL). All
44 unencapsulated isolates showing the PFGE pattern C
(ST344 and ST3097) were multidrug-resistant, showing non-
susceptibility to penicillin, erythromycin, clindamycin, tetra-
cycline and trimethoprim-sulfamethoxazole. No differences in
the susceptibility of ST3097 and ST344 isolates were found.
The 70 isolates studied with PFGE pattern D (ST448) showed
full antimicrobial susceptibility.
The rate of antimicrobial-susceptible isolates was higher
among isolates causing ocular infections other than conjunc-
tivitis (Table 2). All isolates were amoxicillin and ciprofloxacin
susceptible and only one isolate causing endophthalmitis had a
cefotaxime MIC >1 lg/mL (serotype 6B, penicillin and cefo-
taxime MIC = 2 lg/mL).
Discussion
Few studies addressing the epidemiology of pneumococcal
conjunctivitis have been able to analyse the distribution of
pneumococcal serotypes from a single region over a broadT
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time period. In the present study, the isolates from 612
episodes of conjunctivitis and 36 non-conjunctival infections
were widely characterized. In all unencapsulated isolates, the
lack of the capsule was confirmed and all encapsulated isolates
were serotyped. Most cases of conjunctivitis occurred in
children aged <5 years, in contrast to more severe non-
conjunctival ocular infections, which were mostly observed in
older patients. Conjunctival mixed infections of pneumococci
and other bacterial pathogen, mainly non-encapsulated H. in-
fluenzae, were common. The high prevalence of mixed
infections and the greater role of H. influenzae in these
infections have also been observed in acute otitis media
episodes [20,21]. Mixed infections were less common in non-
conjunctival ocular infections (11.1%).
In contrast to many other pneumococcal infections, the
presence of capsule seems not to be an important factor in
causing superficial ocular disease. The association of non-
typeable pneumococci with conjunctivitis was first reported by
Finland and Barnes in 1977 [9], and was later confirmed by
other studies [12,22]. One of these studies assessed the disease
potential of individual serotypes to cause acute conjunctivitis
and concluded that non-typeable and serotype 3 pneumococci
had a positive association with acute conjunctivitis, whereas
non-typeable isolates had a negative association with invasive
TABLE 4. Comparison of antimicrobial non-susceptibility of Streptococcus pneumoniae serotypes causing conjunctivitis included
in the PCV7, non-PCV7 serotypes and unencapsulated isolates in Donostialdea and adjacent populations (Gipuzkoa, northern
Spain, 1999–2010)
MIC in lg/mL
Encapsulated
PCV7
(n = 84)
Encapsulated
non-PCV7
(n = 315)
Unencapsulated
(n = 213)
Total
(n = 612)
Penicillin  0.12 26 31% 52 16.5% 105 49.3% 183 29.9%
 2 8 9.5% 8 2.5% 3 1.4% 19 3.1%
Amoxicillin  4 3 3.6% 7 2.2% 1 0.5% 11 1.8%
Cefotaxime  2 5 6% 3 1% 2 0.9% 10 1.6%
Erythromycin  0.5 35 41.7% 80 25.4% 58 27.2% 173 28.3%
Clindamycin  0.5 32 38.1% 66 21% 46 21.6% 144 23.5%
Tetracycline  4 31 46.3% 69 21.9% 54 25.4% 154 25.2%
Trimethoprim-sulfamethoxazole  1/19 26 31% 91 28.9% 129 60.6% 246 40.2%
Chloramphenicol  8 2 2.4% 4 1.3% 0 0% 6 1%
Rifampicin  2 1 1.2% 11 3.5% 3 1.4% 15 2.5%
Ciprofloxacin  4 1 1.2% 9 2.9% 2 0.9% 12 2%
TABLE 5. Evolution of antimicrobial non-susceptibility of Streptococcus pneumoniae isolates causing conjunctivitis in Donostial-
dea and adjacent populations (Gipuzkoa, northern Spain, 1999–2010)
MIC in
lg/mL
1999–2001
(n = 63)
2002–04
(n = 117)
2005–07
(n = 242)
2008–10
(n = 190)
Penicillin  0.12 28 44.4% 50 42.7% 66 27.3% 39 20.5%
 2 5 7.9% 6 5.1% 1 0.4% 7 3.7%
Amoxicillin  4 2 3.2% 4 3.4% 0 0% 5 2.6%
Cefotaxime  2 4 6.3% 2 1.7% 0 0% 4 2.1%
Erythromycin  0.5 20 31.7% 40 34.2% 66 27.3% 47 24.7%
Clindamycin  0.5 16 25.4% 37 31.6% 53 21.9% 38 20%
Tetracycline  4 22 34.9% 42 35.9% 50 20.7% 40 21.1%
Trimethoprim-sulfamethoxazole  1/19 29 46% 58 49.6% 104 43% 55 28.9%
Chloramphenicol  8 2 3.2% 3 2.6% 1 0.4% 0 0%
Rifampicin  2 5 7.9% 7 6% 2 0.8% 1 0.5%
Ciprofloxacin  4 1 1.6% 2 1.7% 5 2.1% 4 2.1%
TABLE 3. Pulsed-field gel electrophoresis (PFGE), multilocus sequence-genotype (clonal complex (CC) and sequence-type (ST))
and susceptibility pattern of 213 unencapsulated pneumococci causing conjunctivitis
PFGE
Genotype (number studied)a
Predominant non-susceptibility
pattern (percentage)bPattern Number Percentage
A 49 23.0% CC941 ST 941 (5) ST 942 (5) PEN, TMP/SMZ (67.3%)
B 13 6.1% CC941 ST 941 (3) ST 942 (2) PEN, TMP/SMZ (92.3%)
C 44 20.7% CC344 ST 344 (2) ST 3097 (10) PEN, ERY, CLI, TET, TMP/SMZ (100%)
D 70 32.9% CC448 ST 448 (9) Susceptible (100%)
Others 27 37 17.4% – – – PEN, ERY, CLI, TET, TMP/SMZ (18.9%)
aNumber of fully sequenced isolates. In another 39 isolates in patterns A, 8 in pattern B and 32 in pattern C, the ddl, ddl and gdh allele were sequenced, respectively.
bPercentage of total isolates in each PFGE pattern.
PEN, penicillin, ERY, erythromycin, CLI, clindamycin, TET, tetracycline, TMP/SMZ, trimethoprim-sulfamethoxazole.
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disease and acute otitis media [22]. Non-typeable (probably
unencapsulated) isolates have also been responsible for many
large and long-lasting outbreaks of conjunctivitis [2,10,11].
In this study, about one-third (34.8%) of pneumococci
causing acute conjunctivitis were unencapsulated, a percentage
higher than the 12% and 23.2% described in other works
[12,22,23]. In addition, when the present data were compared
with the low rate of unencapsulated pneumococci detected in
invasive and otic infections from this same region [24,25] the
predilection of unencapsulated strains with conjunctivitis was
evident. Molecular characterization of all unencapsulated
isolates revealed that ST941 and ST942 were the main clones
until 2006 but were completely displaced since 2007 by ST448.
ST448 was the clone that caused several outbreaks in the USA
[10,11] and has been also referred to in epidemiological studies
on sporadic cases of conjunctivitis performed in Spain between
1997 and 2002 and in Israel between 2000 and 2004 [12,26]. In
the Spanish study, conjunctival unencapsulated strains were
grouped in only two clusters: CC941 (ST941, ST942 and
ST943) and CC344 (ST344) [12], and neither ST448 nor
ST3097 were found. Moreover, CC941 isolates were suscep-
tible to all antimicrobials, whereas in our study, most CC941
isolates showed trimethoprim-sulfamethoxazole and penicillin
resistance. Unencapsulated ST448 isolates were present in
Gipuzkoa several years before the study period. One ST448
isolate obtained from a 52-year-old with conjunctivitis was
detected in our laboratory in 1995 (data not shown).
All ST448 isolates from the present study were susceptible
to all the antimicrobial agents tested, in accordance with the
susceptibility showed by ST448 isolates in outbreaks in the USA
[11] but unlike the frequently penicillin non-susceptible isolates
closely related to ST448 (CC448) from Israel [27]. CC344
isolates were multidrug-resistant, showing non-susceptibility to
penicillin, trimethoprim-sulfamethoxazole, erythromycin, clin-
damycin and tetracycline. CC344 from other studies from Spain
and Israel were also multidrug-resistant [12,26].
Although unencapsulated isolates were the most prevalent
type causing conjunctivitis, most sporadic cases of conjuncti-
vitis (65.2%) in the 12 years of the study were due to
encapsulated isolates.
In the pre-PCV7 period (1999–2001), serotypes included in
the PCV7 represented 34.9%, the most prevalent serotype
being 19F. The incidence of conjunctivitis due to PCV7
serotypes decreased throughout the study, accounting for only
3.2% of conjunctivitis episodes from 2008 to 2010, in
agreement with the evolution of serotypes causing invasive
disease or otitis in our region [20,25]. In general, antimicrobial
resistance decreased over the study period, mainly because of
a reduction in the prevalence of multidrug-resistant PCV7
serotypes and the increase of antimicrobial-susceptible CC448
unencapsulated isolates. Nevertheless, from 2008 to 2010 the
percentage of isolates with a penicillin MIC >1 lg/mL and
amoxicillin resistance increased as a consequence of the
incursion of multidrug-resistant serotype 19A ST320 isolates.
The spread of these multidrug-resistant serotype 19A, ST320
isolates in our region from 2008 to 2010 was most evident in
isolates causing acute otitis media [24].
Few studies have described serotypes causing pneumococ-
cal conjunctivitis and most were performed with isolates
mainly obtained before PCV7 was introduced, the most
prevalent serotypes being those included in the PCV7, mainly
serotypes 19F, 14, 23F and the non-PCV7 serotype 6A
[12,22,23]. To our knowledge, this is the first study of
pneumococcal conjunctivitis showing a decrease in PCV7
serotypes after the introduction of the PCV7.
The presence of the capsule is a virulence factor that is not
required to cause conjunctivitis or colonization [27], but it is
still unknown why unencapsulated strains take advantage when
causing conjunctivitis, especially during outbreaks. Some
authors have pointed out that the absence of the capsule
may facilitate interactions between one or more surface-
expressed pneumococcal proteins and the conjunctival
mucous surface [28]. Ophthalmic infections other than con-
junctivitis caused by pneumococci had previously been
reported, although this microorganism was an infrequent
cause [4,29]. Pneumococcal keratitis is a relatively common
infection but, in this study, only severe keratitis with a wide
corneal suppuration area, scleral suppuration and/or deep
ulcer of the cornea were included. Few studies have analysed
the serotype distribution of pneumococcal ophthalmic infec-
tions such as endophthalmitis, keratitis or dacryocystitis. In this
work, we found no association between a single serotype and
any of these other ocular infections: nine of the ten episodes of
keratitis and 14 of the 18 episodes of endophthalmitis were
caused by different serotypes. Other authors observed the
same serotype heterogeneity in pneumococcal isolates in non-
conjunctival infections [5,30]. Only one episode of non-
conjunctival infection was caused by an unencapsulated isolate.
Endophthalmitis involves ocular cavity infection and conse-
quently invasiveness properties are necessary. The relevance
of the pneumococcal capsule as a virulence factor in endoph-
thalmitis has also been proved in animal models [31].
In conclusion, unencapsulated isolateswere rare in severenon-
conjunctival infections but represented one-third of the episodes
of acute conjunctivitis. Most unencapsulated isolates belonged to
a few genotypes and, although they changed over time, their
overall prevalence remained stable. In contrast, the serotype
distribution of encapsulated pneumococci causing conjunctivitis
was highly influenced by the introduction of the PCV7, and
serotypes contained in this vaccine almost disappeared.
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